{"log_id": 1296406898135838301, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 0.015349, "average": 0.935476, "min": 0.540267}, "location": {"width": 827, "top": 151, "height": 32, "left": 181}, "words": "俏本上大物外全为白种男性,同性恋,平均年龄为38岁,ADS晚期,扩展性卡波氏"}, {"probability": {"variance": 0.019909, "average": 0.941301, "min": 0.442056}, "location": {"width": 827, "top": 201, "height": 34, "left": 181}, "words": "肉幅,表见为CD4细胞数低.临床试验组中AIDS病人多数为低危病人)。参加试验的病人"}, {"probability": {"variance": 0.016212, "average": 0.936539, "min": 0.610157}, "location": {"width": 452, "top": 252, "height": 29, "left": 180}, "words": "在与艾病相关的卡波氏肉瘤病人中具有代表性"}, {"probability": {"variance": 0.018171, "average": 0.950773, "min": 0.451768}, "location": {"width": 778, "top": 301, "height": 35, "left": 228}, "words": "247例两人参加的第一项研究是以盐酸多柔比星脂质体进行的无对照开放的多中心"}, {"probability": {"variance": 0.019761, "average": 0.93841, "min": 0.499051}, "location": {"width": 827, "top": 351, "height": 36, "left": 181}, "words": "试验,病人拔受的平均剂量为20mg/m2,共接受2015个治疗周期,治疗间隔为2周。临床"}, {"probability": {"variance": 0.00945, "average": 0.963533, "min": 0.607148}, "location": {"width": 454, "top": 400, "height": 29, "left": 179}, "words": "终点包括治疗反应和生活质量。该研究结果如下"}, {"probability": {"variance": 0.00104, "average": 0.972846, "min": 0.912693}, "location": {"width": 135, "top": 450, "height": 25, "left": 323}, "words": "完全缓解(CR"}, {"probability": {"variance": 1e-06, "average": 0.999203, "min": 0.997953}, "location": {"width": 43, "top": 456, "height": 22, "left": 808}, "words": "63%"}, {"probability": {"variance": 0.003336, "average": 0.970252, "min": 0.819531}, "location": {"width": 150, "top": 492, "height": 26, "left": 325}, "words": "部分缓解(PR)"}, {"probability": {"variance": 0.000831, "average": 0.98357, "min": 0.926003}, "location": {"width": 49, "top": 497, "height": 21, "left": 803}, "words": "74.4%"}, {"probability": {"variance": 6.7e-05, "average": 0.992403, "min": 0.974824}, "location": {"width": 107, "top": 534, "height": 24, "left": 344}, "words": "稳定(SD)"}, {"probability": {"variance": 0.000131, "average": 0.992343, "min": 0.97263}, "location": {"width": 45, "top": 542, "height": 20, "left": 806}, "words": "8.5%"}, {"probability": {"variance": 0.000392, "average": 0.985989, "min": 0.948133}, "location": {"width": 136, "top": 577, "height": 24, "left": 323}, "words": "疾病进展(PD"}, {"probability": {"variance": 2.2e-05, "average": 0.996414, "min": 0.98851}, "location": {"width": 44, "top": 585, "height": 20, "left": 805}, "words": "0.8%"}, {"probability": {"variance": 0.004696, "average": 0.984793, "min": 0.577887}, "location": {"width": 781, "top": 620, "height": 37, "left": 223}, "words": "在进行的长期随访中,仅有部分病人接受上市推荐的用药方案,对不同用药方案的疗"}, {"probability": {"variance": 0.021608, "average": 0.926761, "min": 0.441244}, "location": {"width": 838, "top": 668, "height": 48, "left": 174}, "words": "数反应进行统计学分析,差异不显著。到目前为止,平均缓解持续时间为少物医药姆"}, {"probability": {"variance": 0.003484, "average": 0.9772, "min": 0.791873}, "location": {"width": 258, "top": 716, "height": 33, "left": 173}, "words": "关的生活质数据有所改善"}, {"probability": {"variance": 0.019624, "average": 0.92847, "min": 0.352764}, "location": {"width": 817, "top": 758, "height": 55, "left": 221}, "words": "37例艾滋病相关的卡波氏肉瘤病人参加的第二项研究是无对照开放验多柔"}, {"probability": {"variance": 0.025338, "average": 0.932261, "min": 0.376502}, "location": {"width": 831, "top": 808, "height": 51, "left": 170}, "words": "比脂质体的中位剂为20mgm2,3周重复一次共进行793个治疗周期价累计剂"}, {"probability": {"variance": 0.026575, "average": 0.907035, "min": 0.470498}, "location": {"width": 243, "top": 866, "height": 26, "left": 174}, "words": "为110mg/m,有效率如下"}, {"probability": {"variance": 0.018969, "average": 0.934197, "min": 0.598047}, "location": {"width": 140, "top": 912, "height": 26, "left": 318}, "words": "完全缓解(CR"}, {"probability": {"variance": 0.067908, "average": 0.73904, "min": 0.47845}, "location": {"width": 22, "top": 922, "height": 21, "left": 815}, "words": "9%"}, {"probability": {"variance": 4.6e-05, "average": 0.993531, "min": 0.98066}, "location": {"width": 152, "top": 955, "height": 26, "left": 318}, "words": "部分缓解(PR)"}, {"probability": {"variance": 0.003166, "average": 0.96215, "min": 0.853415}, "location": {"width": 55, "top": 962, "height": 21, "left": 795}, "words": "61.8%"}, {"probability": {"variance": 0.005668, "average": 0.945041, "min": 0.783154}, "location": {"width": 106, "top": 997, "height": 24, "left": 338}, "words": "稳定(SD)"}, {"probability": {"variance": 0.007911, "average": 0.953752, "min": 0.775885}, "location": {"width": 53, "top": 1003, "height": 21, "left": 795}, "words": "26.5%"}, {"probability": {"variance": 0.001064, "average": 0.979517, "min": 0.917121}, "location": {"width": 146, "top": 1039, "height": 23, "left": 317}, "words": "疾病进展(PD)"}, {"probability": {"variance": 0.001342, "average": 0.989091, "min": 0.778613}, "location": {"width": 785, "top": 1079, "height": 39, "left": 215}, "words": "从有效性和所有病人(包括以前接受过化疗的)疼痛的减轻来看,从该研究获得的结"}, {"probability": {"variance": 0.007364, "average": 0.975091, "min": 0.496961}, "location": {"width": 832, "top": 1128, "height": 38, "left": 168}, "words": "果是令人鼓前,中位缓解持续时间为92天。截至研究结束时,共有37例病人死亡,生存"}, {"probability": {"variance": 0.00595, "average": 0.959314, "min": 0.772988}, "location": {"width": 192, "top": 1177, "height": 29, "left": 171}, "words": "的延长效果不显"}, {"probability": {"variance": 0.00448, "average": 0.978745, "min": 0.645861}, "location": {"width": 783, "top": 1225, "height": 36, "left": 215}, "words": "两维研究的分析根据白血球减少症、全身性疾病(包括机会性感染)CD4细胞数进行"}, {"probability": {"variance": 0.015961, "average": 0.943752, "min": 0.522513}, "location": {"width": 527, "top": 1271, "height": 35, "left": 164}, "words": "了整,并发现原患有粒细胞减少症的病人(ANC<20"}, {"probability": {"variance": 0.000768, "average": 0.979527, "min": 0.91304}, "location": {"width": 258, "top": 1277, "height": 28, "left": 742}, "words": "mm3)的整体反应率(的3y"}, {"probability": {"variance": 0.003355, "average": 0.968358, "min": 0.736085}, "location": {"width": 742, "top": 1315, "height": 46, "left": 167}, "words": "与拉细胞基础水平高的患者相同(76.6%)。同样,全身性疾病基础水平风险的病"}, {"probability": {"variance": 0.006977, "average": 0.96374, "min": 0.61647}, "location": {"width": 864, "top": 1360, "height": 67, "left": 187}, "words": "低风险的病人68%)的治疗反应率也相似。CD4计数有关的情况是地数量<"}, {"probability": {"variance": 0, "average": 0.946512, "min": 0.946512}, "location": {"width": 30, "top": 1402, "height": 27, "left": 877}, "words": "将"}, {"probability": {"variance": 0.004319, "average": 0.963847, "min": 0.625558}, "location": {"width": 759, "top": 1417, "height": 39, "left": 272}, "words": "和CD4>50 cells/inm3的病人反应率相似。然而,<50 Ocells/mm的患者中有2"}, {"probability": {"variance": 0.008889, "average": 0.970461, "min": 0.528603}, "location": {"width": 519, "top": 1465, "height": 32, "left": 173}, "words": "%全缓解,CD4水平最高的患者中有10%完全缓解"}, {"probability": {"variance": 0.012538, "average": 0.943992, "min": 0.4587}, "location": {"width": 783, "top": 1511, "height": 40, "left": 209}, "words": "为了充分训明盐酸多柔比星脂质体的有效性,进行了盐酸多柔比星脂质体(20mng/m2)"}, {"probability": {"variance": 0.018616, "average": 0.922198, "min": 0.463278}, "location": {"width": 803, "top": 1558, "height": 40, "left": 188}, "words": "ABV丨多柔比星(20mg/m3)、博莱霉素(10U/m2)及长春新碱(1mg/m2)]的前瞻性随机"}], "language": 3}